https://scholars.lib.ntu.edu.tw/handle/123456789/624377
標題: | Gut-oriented disease modifying therapy for Parkinson's disease | 作者: | CHIN-HSIEN LIN HSIN-CHIH LAI MING-SHIANG WU |
關鍵字: | Gut microbiota; Gut–brain axis; Live biotherapeutic product; Parkinson's disease; Probiotics | 公開日期: | 一月-2023 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Neuropathology studies have shown that the pathognomonic feature of Parkinson's disease (PD), one of the most common neurodegenerative disorders, may start from the gut enteric nervous system and then spread to the central dopaminergic neurons through the gut-brain axis. With the advent of metagenomic sequencing and metabolomic analysis, a plethora of evidence has revealed different gut microbiomes and gut metabolites in patients with PD compared with unaffected controls. Currently, although dopaminergic treatments and deep brain stimulation can provide some symptomatic benefits for motor symptoms of the disease, their long-term use is problematic. A mechanism-targeted therapy to halt the neurodegeneration is lacking. The recently observed gut microenvironmental changes in the early stages of the disease play a vital role in the PD pathogenesis. Patients whose disease begins in the gut may benefit most from interventions that target the gut microenvironments. In this review, we will summarize the current studies demonstrating multifunctional roles of gut microbiota in the gut-brain axis of PD and the currently available evidence for targeting the gut microbiota as a novel approach to potential disease-modifying therapy in PD. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/624377 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2022.09.010 |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。